Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | REN | P00797 | 4/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 4/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278355 | 0.85 | NPY5R (0.39) | NPY5RMETAP2METAP1HTR2CSLC6A4 | |
| SCHEMBL23022839 | 0.85 | ATM (0.47) | NPY5RHTR2CSLC6A4RENATM | |
| SCHEMBL23005007 | 0.85 | NPY5R (0.45) | NPY5RMETAP2METAP1ATM | |
| SCHEMBL30278360 | 0.81 | BCHE (0.41) | NPY5RMETAP2METAP1BCHEACHE | |
| SCHEMBL5010708 | 0.80 | AAK1 (0.38) | AAK1 | |
| SCHEMBL30278364 | 0.80 | GPR119 (0.40) | NPY5RHTR2CSLC6A4RENTDP1 | |
| SCHEMBL30278292 | 0.79 | NPY5R (0.37) | NPY5RMETAP2METAP1HTR2CSLC6A4 | |
| SCHEMBL30278378 | 0.78 | USP30 (0.42) | NPY5RHTR2CSLC6A4ATMTDP1 | |
| SCHEMBL30278346 | 0.76 | METAP2 (0.35) | NPY5RMETAP2METAP1HTR2CSLC6A4 | |
| SCHEMBL1491455 | 0.76 | CACNA1B (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | NPY5R 3819/4885METAP2 819/4885METAP1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.